Liminatus Pharma, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Is Liminatus Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of October 1, 2023, Liminatus Pharma, Inc. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, and moving averages, alongside a year-to-date return of -88.5%, significantly underperforming the S&P 500's 12.22%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 63 Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.27

Return on Equity

-999,999.00%

Price to Book

-62.52

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-57.45%

6 Months

-95.82%

1 Year

-92.48%

2 Years

-91.77%

3 Years

-91.55%

4 Years

-91.37%

5 Years

0.0%

Liminatus Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Liminatus Pharma, Inc. technically bullish or bearish?

As of 1 October 2023, the technical trend for Liminatus Pharma, Inc. is bearish. Key indicators driving this stance include bearish signals from the MACD on both weekly and monthly time frames, bearish Bollinger Bands, and bearish moving averages on the daily chart. Additionally, the KST and Dow Theory also indicate bearish trends on both weekly and monthly levels. The OBV shows a mildly bearish stance on the weekly but no trend on the monthly. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -88.5% compared to the S&P 500's 12.22%....

Liminatus Pharma Stock Plummets to New 52-Week Low of $1.24

Liminatus Pharma, Inc. has reached a new 52-week low, reflecting its challenging performance compared to the S&P 500. With a market cap of USD 63 million, the company faces significant hurdles, including a negative price-to-book ratio and a troubling return on equity, highlighting the volatility in the biotechnology sector.

Liminatus Pharma Stock Plummets to New 52-Week Low of $1.58

Liminatus Pharma, Inc. has reached a new 52-week low of USD 1.58, contrasting sharply with its previous high of USD 33.66. The company, with a market cap of USD 63 million, faces significant financial challenges, including a negative return on equity and a unique debt-to-equity ratio.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

6.22%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

EV to EBITDA

EV to Capital Employed

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 100.00% vs -50.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.00",
          "val2": "-0.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.00",
          "val2": "-0.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -141.67% vs -111.76% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-2.60",
          "chgp": "-11.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.90",
          "val2": "-1.20",
          "chgp": "-141.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.00

-0.50

100.00%

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

-0.20

100.00%

Consolidate Net Profit

-0.00

-0.90

100.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 100.00% vs -50.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.90

-2.60

-11.54%

Interest

0.10

Exceptional Items

0.00

0.90

-100.00%

Consolidate Net Profit

-2.90

-1.20

-141.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -141.67% vs -111.76% in Dec 2023

All Annual Results

Company CV

About

Company Coordinates

Company Details

Tel:

Registrar Details

Liminatus Pharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

Is Liminatus Pharma, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Liminatus Pharma, Inc. technically bullish or bearish?

Liminatus Pharma Stock Plummets to New 52-Week Low of $1.24

Liminatus Pharma Stock Plummets to New 52-Week Low of $1.58

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About

Company Coordinates